These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1068 related articles for article (PubMed ID: 33920789)
1. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers. Barwal TS; Sharma U; Bazala S; Singh I; Jain M; Prakash H; Shekhar S; Sandberg EN; Bishayee A; Jain A Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920789 [TBL] [Abstract][Full Text] [Related]
2. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. Panoutsopoulou K; Avgeris M; Scorilas A Expert Rev Mol Diagn; 2018 Nov; 18(11):963-979. PubMed ID: 30338716 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data. Xiao B; Zhang W; Chen L; Hang J; Wang L; Zhang R; Liao Y; Chen J; Ma Q; Sun Z; Li L Gene; 2018 Jun; 658():28-35. PubMed ID: 29518546 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049 [TBL] [Abstract][Full Text] [Related]
6. Interplay Between Long Noncoding RNAs and MicroRNAs in Cancer. Russo F; Fiscon G; Conte F; Rizzo M; Paci P; Pellegrini M Methods Mol Biol; 2018; 1819():75-92. PubMed ID: 30421400 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer. Shao X; Huang P; Shi L; Lei L; Cao W; Chen Z; Wang X; Zheng Y Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775882 [TBL] [Abstract][Full Text] [Related]
8. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Ingle JN; Xie F; Ellis MJ; Goss PE; Shepherd LE; Chapman JW; Chen BE; Kubo M; Furukawa Y; Momozawa Y; Stearns V; Pritchard KI; Barman P; Carlson EE; Goetz MP; Weinshilboum RM; Kalari KR; Wang L Cancer Res; 2016 Dec; 76(23):7012-7023. PubMed ID: 27758888 [TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. Shibahara Y; Miki Y; Onodera Y; Hata S; Chan MS; Yiu CC; Loo TY; Nakamura Y; Akahira J; Ishida T; Abe K; Hirakawa H; Chow LW; Suzuki T; Ouchi N; Sasano H J Pathol; 2012 Jul; 227(3):357-66. PubMed ID: 22407818 [TBL] [Abstract][Full Text] [Related]
10. Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278 [TBL] [Abstract][Full Text] [Related]
11. Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies. Manna PR; Molehin D; Ahmed AU Prog Mol Biol Transl Sci; 2016; 144():487-537. PubMed ID: 27865465 [TBL] [Abstract][Full Text] [Related]
12. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Nagini S Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076 [TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835 [TBL] [Abstract][Full Text] [Related]
14. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications. Hanamura T; Hayashi SI Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808 [TBL] [Abstract][Full Text] [Related]
15. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. Venkatesh J; Wasson MD; Brown JM; Fernando W; Marcato P Cancer Lett; 2021 Jul; 509():81-88. PubMed ID: 33848519 [TBL] [Abstract][Full Text] [Related]
16. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines. Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600 [TBL] [Abstract][Full Text] [Related]
17. Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers. Sanchez Calle A; Yamamoto T; Kawamura Y; Hironaka-Mitsuhashi A; Ono M; Tsuda H; Shimomura A; Tamura K; Takeshita F; Ochiya T; Yamamoto Y Mol Oncol; 2020 Sep; 14(9):2271-2287. PubMed ID: 32392629 [TBL] [Abstract][Full Text] [Related]
18. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468 [TBL] [Abstract][Full Text] [Related]
19. Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma. Lim LJ; Wong SYS; Huang F; Lim S; Chong SS; Ooi LL; Kon OL; Lee CG Cancer Res; 2019 Oct; 79(20):5131-5139. PubMed ID: 31337653 [TBL] [Abstract][Full Text] [Related]
20. Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers. Klinge CM Endocr Relat Cancer; 2018 Apr; 25(4):R259-R282. PubMed ID: 29440232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]